Correlation between MEK signature and Ras gene alteration in advanced gastric cancer

MEK inhibitor (selumetinib) is a potent, orally active inhibitor of MAPK/ERK pathway. It is important to develop an accurate and robust method indicative of RAS pathway activity to stratify potential patients who can benefit from selumetinib treatment in gastric cancer (GC). First, we surveyed the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Soomin, Brant, Roz, Sharpe, Alan, Dry, Jonathan R., Hodgson, Darren R., Kilgour, Elaine, Kim, Kyung, Kim, Seung Tae, Park, Se Hoon, Kang, Won Ki, Kim, Kyoung-Mee, Lee, Jeeyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746083/
https://www.ncbi.nlm.nih.gov/pubmed/29296181
http://dx.doi.org/10.18632/oncotarget.18182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746083/
https://www.ncbi.nlm.nih.gov/pubmed/29296181
http://dx.doi.org/10.18632/oncotarget.18182

Ejemplares similares